In his letter, Dr. Alexander Sigalov suggests an alternative interpretation to our results mapping the domain of FP that mediates the interaction with the TCR to the FP 5-13 region (1). He suggests that, in addition to FP 5-13 , the C-terminus domain of FP 1-32 contains a region capable of inserting itself into the membrane and interacting with the CD3 subunits of the TCR, thereby impairing TCR function. We consider this alternative explanation unlikely for several reasons. First, we have synthesized and investigated FP 17-32 and found it inactive in all assays (unpublished data). Second, a mutant FP 1-32 termed V2E shows a diminished ability to interfere with the activation of T cells both in vivo and in vitro (2), despite the fact that the mutation in V2E is located in the N-terminus and not in the C-terminus of FP 1-32 . Thus, if any inhibitory activity resides on the C-terminus of FP 1-32 , it must be secondary to the activity of the N-terminus. Thirdly, the current working model describing the mechanism of action of FP 1-32 during membrane fusion in HIV infection suggests that FP 1-16 inserts into the target T-cell membrane, while the FP 17-32 region does not insert, but remains positioned parallel to the cell membrane (ref 1 , Fig. 1) (3, 4) . This positioning of the different domains of FP 1-32 does not allow the FP 17-32 region to insert into the membrane and interact with the CD3 subunits of the TCR complex as suggested by Sigalov.
In his letter, Dr. Alexander Sigalov suggests an alternative interpretation to our results mapping the domain of FP that mediates the interaction with the TCR to the FP 5-13 region (1) . He suggests that, in addition to FP 5-13 , the C-terminus domain of FP 1-32 contains a region capable of inserting itself into the membrane and interacting with the CD3 subunits of the TCR, thereby impairing TCR function. We consider this alternative explanation unlikely for several reasons. First, we have synthesized and investigated FP 17-32 and found it inactive in all assays (unpublished data). Second, a mutant FP 1-32 termed V2E shows a diminished ability to interfere with the activation of T cells both in vivo and in vitro (2) , despite the fact that the mutation in V2E is located in the N-terminus and not in the C-terminus of FP . Thus, if any inhibitory activity resides on the C-terminus of FP , it must be secondary to the activity of the N-terminus. Thirdly, the current working model describing the mechanism of action of FP 1-32 during membrane fusion in HIV infection suggests that FP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] inserts into the target T-cell membrane, while the FP 17-32 region does not insert, but remains positioned parallel to the cell membrane (ref 1, Fig. 1) (3, 4) . This positioning of the different domains of FP does not allow the FP 17-32 region to insert into the membrane and interact with the CD3 subunits of the TCR complex as suggested by Sigalov.
The alternative interpretation suggested by Sigalov is based on the different potency manifested by FP 1-32 , FP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and FP 5-13 in Figs. 1 and 7 of our manuscript (1). However, a careful comparison of Figs. 1 and 7 reveals that FP 1-32 and FP 5-13 have similar inhibitory efficiencies; moreover FP 1-32 and FP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (Fig. 2) have similar activities in vivo. Thus, we attribute the differences in the efficiency of FP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and FP 1-32 not as an indicator of the existence of another independent inhibitory region, but as the result of the different solubility and state of aggregation of the different peptides; this effect seems to be more important for in vitro assays (Fig. 1) , but less important for in vivo assays (Fig. 2) . Indeed, FP 1-32 is known to form oligomers (2, 4); this multimerization is facilitated by the C-terminus increasing fusogenic activity of FP (3, 4) . Whether multimerization plays a role in the immunomodulatory activities of FP and its peptides is still unknown. Nevertheless, we believe that the above-mentioned data rule out the alternative interpretation put forward by Sigalov, that the C terminus region of FP 1-32 plays a significant role in its immunomodulatory activity.
